RE:Roche in-licenses USP-1 small molecule to PARP inhibitorPrior to the signing of the Inflation Reduction Act (IRA) in August 2022 Big Pharma was actively pursuing small molecule acquisition and development.
With the passage of the IRA, small molecules were provided 9 years of FDA marketing exclusivity while biologicals were provided 13 years to FDA marketing exclusivity on the date of FDA approval.
Now Big Pharma is seeking to transition their pipeline and business model to Biotech/Biophama. Some have yet to understand this transition to the era of Precision Medicine and biological therapy.
https://www.fiercebiotech.com/biotech/roche-pays-repare-125m-join-big-pharma-peers-cancer-race